Open Internet by MindsNet

Limited access to unapproved peptides

The FDA's current stance on unapproved peptides may limit access to potentially beneficial treatments. This restriction could hinder medical progress and patient care. The issue revolves around balancing regulatory control with the need for innovation in pharmacology.

Science, Medicine, Pharmacology